Efficacy and safety of short duration radiotherapy combined with chemotherapy for advanced rectal cancer

Table 1 Differences in the expression of Runx3 and Ki-67 from the biopsy between two groups before and after the treatment, n (%)

Groups	n	Time point	Runx3		Ki-67
			Positive	Negative	Positive	Negative
Observation group	50	Before the treatment	26 (2.0)	24 (48.0)	46 (92.0)	4 (8.0)
		After the treatment	38 (76.0)a	12 (24.0)	37 (74.0)a	12 (26.0)
Control group	50	Before the treatment	27 (54.0)	23 (46.0)	45 (90.0)	5 (10.0)
		After the treatment	34 (68.0)a	16 (32.0)	36 (72.0)a	14 (28.0)

Compared with those before the treatment.

^aP < 0.05.

Table 2 Differences in the incidence of chemoradiotherapy-induced adverse reactions between the two groups before the operation, n (%)

Groups	n	Anemia	Leukopenia	Thrombocytopenia	Neutropenia	Diarrhea	Fatigue	Neurotoxicity	Nausea and vomiting
Observation group	50	24 (48.0)	31 (62.0)a	36 (72.0)a	31 (62.0)a	17 (34.0)a	9 (18.0)	11 (22.0)	23 (46.0)
Control group	50	22 (44.0)	20 (40.0)	24 (48.0)	22 (44.0)	9 (18.0)	8 (16.0)	12 (24.0)	22 (24.0)

Compared with the control group.

^aP < 0.05.

Table 3 Comparison of operation indices between the two groups, n (%)

Groups	n	Duration of surgery (min)	Intraoperative blood loss (mL)	Anal conservation rate	Postoperative complications
					Surgery incision infection	Anastomotic leakage	Intestinal obstruction
Observation group	50	234.12 ± 24.56	124.78 ± 15.90	45 (90.0)	2 (4.0)	3 (6.0)	2 (4.0)
Control group	50	215.34 ± 26.71	113.61 ± 16.22	44 (88.0)	3 (6.0)	4 (8.0)	1 (2.0)
t/χ2 value		1.21	1.98	0.28	0.11	0.19	0.21
P value		0.54	0.21	0.75	0.87	0.83	0.74